The maturation of artificial intelligence (AI) and robotic automation technologies is transforming the landscape of global pharmaceutical and biotechnology investment. As platform technologies capable of processing and analyzing large-scale data in real time approach completion—overcoming the limitations of fragmented analysis and manual, labor-intensive research and development—the competition among global companies to secure first-mover advantage has become fiercer than ever.

AI and Automation Reshape Biotech... Global Investment in Innovative Biopharma Technologies Expands View original image

According to industry sources on June 12, Samsung Electronics has accelerated its bid to lead the precision medicine market by participating in the Series E funding round of U.S. gene analysis equipment company Element Biosciences, acquiring an additional $175 million (approximately KRW 262.5 billion) stake and securing the position of largest shareholder. Element Biosciences offers DNA sequencing technology that increases genome analysis accuracy to 99.99% while reducing costs, along with its multi-omics device “AVITI 24,” which can automatically analyze DNA, RNA, proteins, and even changes in cell morphology from a single cell sample. This represents a notable example of overcoming the time and cost constraints of traditional methods—where each type of biological information was analyzed with separate equipment and later combined—through AI and automation technologies. Samsung Electronics’ investment is viewed as a commitment to the global precision medical infrastructure market.


Novartis is also actively adopting AI-based platforms by expanding its strategic partnership with Orionis Biosciences. Orionis possesses the “Allo-Glue” platform, which uses an AI-driven discovery engine and robotic automation to systematically prioritize pairs of target proteins and ligases and identify molecular glue drug candidates. The approach involves administering a molecular glue drug that connects a ligase—acting as a “cleaner”—to a disease-causing target protein (the “causal agent”), thereby inducing the degradation and removal of the target. Novartis has agreed to pay Orionis an upfront $40 million (approximately KRW 60 billion), with additional milestone payments that could total up to $1.4 billion (approximately KRW 2.1 trillion) in future investments.


This shift toward AI and digital diagnostic technologies is also evident in Roche’s strategy. Recently, Roche announced its plan to acquire PathAI—a company specializing in the core infrastructure of AI-powered precision medicine, namely digital pathology systems—for up to $1.05 billion (approximately KRW 1.575 trillion). PathAI’s technology converts microscopic tissue analysis into high-resolution digital images, enabling AI-assisted cancer diagnosis and biomarker analysis, signaling a paradigm shift in the diagnostic market of the future.



According to global market research firm Global Market Insights, the global AI market for new drug development is projected to grow from $3.1 billion (approximately KRW 4.65 trillion) last year to $43.9 billion (approximately KRW 65.85 trillion) by 2035, reflecting an average annual growth rate of over 30%. This market expansion is a result of industry demand to streamline the time and costs required from candidate discovery to clinical trial design by rapidly processing vast volumes of biological data. Moving forward, the pharmaceutical and biotechnology industries are expected to move away from traditional models reliant solely on in-house researchers, instead reorganizing around highly advanced, automated platform ecosystems forged through collaboration with AI companies. An industry insider stated, “The convergence of AI and robotics has become an essential infrastructure for shortening drug development cycles and boosting research efficiency. In the future, the level of digital platform technology and the capacity to utilize data will become the key indicators that determine the competitiveness of pharmaceutical companies.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing